These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34237262)

  • 21. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial.
    Barreto ML; Pereira SM; Pilger D; Cruz AA; Cunha SS; Sant'Anna C; Ichihara MY; Genser B; Rodrigues LC
    Vaccine; 2011 Jul; 29(31):4875-7. PubMed ID: 21616115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The distribution and implications of BCG scars in northern Malawi.
    Fine PE; Ponnighaus JM; Maine N
    Bull World Health Organ; 1989; 67(1):35-42. PubMed ID: 2706726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial.
    Prentice S; Nassanga B; Webb EL; Akello F; Kiwudhu F; Akurut H; Elliott AM; Arts RJW; Netea MG; Dockrell HM; Cose S;
    Lancet Infect Dis; 2021 Jul; 21(7):993-1003. PubMed ID: 33609457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of BCG Revaccination on Occupationally Exposed Medical Personnel Vaccinated against SARS-CoV-2.
    Ramos-Martinez E; Falfán-Valencia R; Pérez-Rubio G; Andrade WA; Rojas-Serrano J; Ambrocio-Ortiz E; Galicia-Álvarez DS; Bárcenas-Montiel I; Velasco-Medina A; Velázquez-Sámano G
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gamma interferon responses induced by a panel of recombinant and purified mycobacterial antigens in healthy, non-mycobacterium bovis BCG-vaccinated Malawian young adults.
    Black GF; Weir RE; Chaguluka SD; Warndorff D; Crampin AC; Mwaungulu L; Sichali L; Floyd S; Bliss L; Jarman E; Donovan L; Andersen P; Britton W; Hewinson G; Huygen K; Paulsen J; Singh M; Prestidge R; Fine PE; Dockrell HM
    Clin Diagn Lab Immunol; 2003 Jul; 10(4):602-11. PubMed ID: 12853392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses: A 60-Year Follow-up of a Clinical Trial.
    Usher NT; Chang S; Howard RS; Martinez A; Harrison LH; Santosham M; Aronson NE
    JAMA Netw Open; 2019 Sep; 2(9):e1912014. PubMed ID: 31553471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of the leprosy component of the Brazilian BCG revaccination trial for assessing BCG effectiveness against leprosy in school children.
    Cunha SS; Dourado I; Barreto ML; Alexander N; Pereira SM; Ichihara Y; Pereira ES; Pedrosa V; Maroja F; Ribas C; Rodrigues LC
    Int J Lepr Other Mycobact Dis; 2004 Mar; 72(1):8-15. PubMed ID: 15217320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
    Ella R; Reddy S; Jogdand H; Sarangi V; Ganneru B; Prasad S; Das D; Raju D; Praturi U; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai S; Panda S; Abraham P; Gupta N; Ella K; Bhargava B; Vadrevu KM
    Lancet Infect Dis; 2021 Jul; 21(7):950-961. PubMed ID: 33705727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis.
    Ghazi Saidi K; Stanford JL; Stanford CA; Dowlati Y; Farshchi Y; Rook GA; Rees RJ
    Int J Lepr Other Mycobact Dis; 1989 Mar; 57(1):45-53. PubMed ID: 2659701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
    Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T;
    Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong.
    Leung CC; Tam CM; Chan SL; Chan-Yeung M; Chan CK; Chang KC
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):717-23. PubMed ID: 11495262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu F; Huang S; Liu X; Chen Q; Zhuang C; Zhao H; Han J; Jaen AM; Do TH; Peter JG; Dorado AG; Tirador LS; Zabat GMA; Villalobos REM; Gueco GP; Botha LLG; Iglesias Pertuz SP; Tan J; Zhu K; Quan J; Lin H; Huang Y; Jia J; Chu X; Chen J; Chen Y; Zhang T; Su Y; Li C; Ye X; Wu T; Zhang J; Xia N;
    Lancet Respir Med; 2023 Dec; 11(12):1075-1088. PubMed ID: 37979588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
    Satti I; Meyer J; Harris SA; Manjaly Thomas ZR; Griffiths K; Antrobus RD; Rowland R; Ramon RL; Smith M; Sheehan S; Bettinson H; McShane H
    Lancet Infect Dis; 2014 Oct; 14(10):939-46. PubMed ID: 25151225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
    Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
    Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.
    Wajja A; Nassanga B; Natukunda A; Serubanja J; Tumusiime J; Akurut H; Oduru G; Nassuuna J; Kabagenyi J; Morrison H; Scott H; Doherty RP; Marshall JL; Puig IC; Cose S; Kaleebu P; Webb EL; Satti I; McShane H; Elliott AM;
    Lancet Infect Dis; 2024 Mar; 24(3):285-296. PubMed ID: 38012890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size.
    Floyd S; Ponnighaus JM; Bliss L; Warndorff DK; Kasunga A; Mogha P; Fine PE
    Int J Tuberc Lung Dis; 2000 Dec; 4(12):1133-42. PubMed ID: 11144455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.